Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma

For nearly a decade, sorafenib has served as a first-line chemotherapeutic drug for the treatment of hepatocellular carcinoma (HCC), but it displays only limited efficacy against advanced drug-resistant HCC. Regorafenib, the first second-line drug approved for treatment after sorafenib failure, can...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Aging (Albany NY)
Hauptverfasser: Zhu, Qiankun, Ren, Haiyang, Li, Xiaodong, Qian, Bo, Fan, Shengjie, Hu, Fengli, Xu, Lishan, Zhai, Bo
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals 2020
Schlagworte:
Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7746348/
https://ncbi.nlm.nih.gov/pubmed/33203790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/aging.104028
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge